Wishing to die or self-harm after stroke: A planned secondary analysis of the AFFINITY Randomised Controlled Trial

AFFINITY Trial Collaboration; Osvaldo P. Almeida; Graeme J. Hankey; Andrew Ford; Christopher Etherton-Beer; Leon Flicker; Maree Hackett

doi:10.1016/j.maturitas.2022.08.011

Wishing to die or self-harm after stroke: A planned secondary analysis of the AFFINITY Randomised Controlled Trial

AFFINITY Trial Collaboration, Osvaldo P. Almeida, Graeme J. Hankey, Andrew Ford, Christopher Etherton-Beer, Leon Flicker, Maree Hackett

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

We investigated the cumulative prevalence of self-harm ideation among stroke survivors of the AFFINITY trial. We assessed these thoughts with the last item of the PHQ-9, and functional impairment with the modified Rankin Scale (mRS). Of 1221 participants (age 63.9 ± 12.3 years, 775 men), 11 reported wishing to die or self-harm at baseline. By week 52, 36 of 1159 surviving participants had reported wishing to die or self-harm. Treatment with fluoxetine for 26 weeks did not change the prevalence of these thoughts compared with placebo. Clinically significant symptoms of depression were present in 95 % of participants with recurrent self-harm thoughts. The study was registered with the Australian and New Zealand Clinical Trials Registry, ACTRN12611000774921.

Original language	English
Pages (from-to)	86-88
Number of pages	3
Journal	Maturitas
Volume	166
DOIs	https://doi.org/10.1016/j.maturitas.2022.08.011
Publication status	Published - Dec 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.maturitas.2022.08.011

Cite this

@article{74a553d4687c48948847b358ad344633,

title = "Wishing to die or self-harm after stroke: A planned secondary analysis of the AFFINITY Randomised Controlled Trial",

abstract = "We investigated the cumulative prevalence of self-harm ideation among stroke survivors of the AFFINITY trial. We assessed these thoughts with the last item of the PHQ-9, and functional impairment with the modified Rankin Scale (mRS). Of 1221 participants (age 63.9 ± 12.3 years, 775 men), 11 reported wishing to die or self-harm at baseline. By week 52, 36 of 1159 surviving participants had reported wishing to die or self-harm. Treatment with fluoxetine for 26 weeks did not change the prevalence of these thoughts compared with placebo. Clinically significant symptoms of depression were present in 95 % of participants with recurrent self-harm thoughts. The study was registered with the Australian and New Zealand Clinical Trials Registry, ACTRN12611000774921.",

keywords = "Cerebrovascular disease, Depression, Self-harm, Stroke, Suicide, Suicide ideation",

author = "{AFFINITY Trial Collaboration} and Almeida, {Osvaldo P.} and Hankey, {Graeme J.} and Andrew Ford and Christopher Etherton-Beer and Leon Flicker and Maree Hackett",

note = "Funding Information: This work was supported by a competitive project grant application (GRNT1059094) from the National Health and Medical Research Council of Australia (NHMRC). The funding agency had no role in the design and conduct of the study; data collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Publisher Copyright: {\textcopyright} 2022",

year = "2022",

month = dec,

doi = "10.1016/j.maturitas.2022.08.011",

language = "English",

volume = "166",

pages = "86--88",

journal = "Maturitas",

issn = "0378-5122",

publisher = "Elsevier",

}

TY - JOUR

T1 - Wishing to die or self-harm after stroke

T2 - A planned secondary analysis of the AFFINITY Randomised Controlled Trial

AU - AFFINITY Trial Collaboration

AU - Almeida, Osvaldo P.

AU - Hankey, Graeme J.

AU - Ford, Andrew

AU - Etherton-Beer, Christopher

AU - Flicker, Leon

AU - Hackett, Maree

N1 - Funding Information: This work was supported by a competitive project grant application (GRNT1059094) from the National Health and Medical Research Council of Australia (NHMRC). The funding agency had no role in the design and conduct of the study; data collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Publisher Copyright: © 2022

PY - 2022/12

Y1 - 2022/12

N2 - We investigated the cumulative prevalence of self-harm ideation among stroke survivors of the AFFINITY trial. We assessed these thoughts with the last item of the PHQ-9, and functional impairment with the modified Rankin Scale (mRS). Of 1221 participants (age 63.9 ± 12.3 years, 775 men), 11 reported wishing to die or self-harm at baseline. By week 52, 36 of 1159 surviving participants had reported wishing to die or self-harm. Treatment with fluoxetine for 26 weeks did not change the prevalence of these thoughts compared with placebo. Clinically significant symptoms of depression were present in 95 % of participants with recurrent self-harm thoughts. The study was registered with the Australian and New Zealand Clinical Trials Registry, ACTRN12611000774921.

AB - We investigated the cumulative prevalence of self-harm ideation among stroke survivors of the AFFINITY trial. We assessed these thoughts with the last item of the PHQ-9, and functional impairment with the modified Rankin Scale (mRS). Of 1221 participants (age 63.9 ± 12.3 years, 775 men), 11 reported wishing to die or self-harm at baseline. By week 52, 36 of 1159 surviving participants had reported wishing to die or self-harm. Treatment with fluoxetine for 26 weeks did not change the prevalence of these thoughts compared with placebo. Clinically significant symptoms of depression were present in 95 % of participants with recurrent self-harm thoughts. The study was registered with the Australian and New Zealand Clinical Trials Registry, ACTRN12611000774921.

KW - Cerebrovascular disease

KW - Depression

KW - Self-harm

KW - Stroke

KW - Suicide

KW - Suicide ideation

UR - http://www.scopus.com/inward/record.url?scp=85137285878&partnerID=8YFLogxK

U2 - 10.1016/j.maturitas.2022.08.011

DO - 10.1016/j.maturitas.2022.08.011

M3 - Article

C2 - 36081217

AN - SCOPUS:85137285878

SN - 0378-5122

VL - 166

SP - 86

EP - 88

JO - Maturitas

JF - Maturitas

ER -

Wishing to die or self-harm after stroke: A planned secondary analysis of the AFFINITY Randomised Controlled Trial

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

An Australasian, multi-centre, randomized, double-blind, placebo-controlled trial of the efficacy of fluoxetine in improving functional recovery after acute stroke / Assessment of FluoxetINe In sTroke recoverY (AFFINITY)

Cite this

Wishing to die or self-harm after stroke: A planned secondary analysis of the AFFINITY Randomised Controlled Trial

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Projects

An Australasian, multi-centre, randomized, double-blind, placebo-controlled trial of the efficacy of fluoxetine in improving functional recovery after acute stroke / Assessment of FluoxetINe In sTroke recoverY (AFFINITY)

Cite this